Hi Bluesky - Biotech is a very risk/reward investment. However, with medically qualified Directors, I would say that PER has a great opportunity to reinvent itself using Science as its basis. I know he gets a fair amount of criticism, but JG is a class act - trust me there are some really shoddy CEOs on the ASX. Let's judge him over the next 12 months for how he runs PER with a blank piece of paper - provided he doesn't get voted out. If PER can bring a drug to market then the business SP will increase significantly.
Unfortunately Greedy Gennadi and PVHell have really delayed the recovery by the 'random' hostile takeover attempts. Gennadi driven by pure delusion and PVHell driven by opportunistic greed. I would say that PER, for it's size, is lucky to have the talent on their existing BOD. JG could probably earn double his salary in a mid Executive role in Big Pharma. It is critical to keep someone with his experience as CEO.
However, time will tell. I have a sizeable holding and feel optimistic.
PER Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)